Acumen Pharmaceuticals, Inc.
ABOS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$2.27
KIRA · Stoqly’s AI analyst, in plain words
- Acumen Pharmaceuticals, Inc. lost $121M in fiscal 2025.
- Free cash flow was −$116M in fiscal 2025, — of revenue.
- Acumen Pharmaceuticals, Inc. has $85.7M more cash than debt.
Market cap
$164M
P/E
—
Revenue
—
Net income
−$121M
Free cash flow
−$116M
Operating margin
—
Acumen Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$121M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Acumen Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Acumen Pharmaceuticals, Inc.
- CIK
- 0001576885
Acumen Pharmaceuticals, Inc. · ABOS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$101M | −$42.9M | −$52.4M | −$102M | −$121M |
| Diluted EPS | −$5.02 | −$1.06 | −$1.08 | −$1.71 | −$2.00 |
| Cash | |||||
| Cash from operations | −$18.0M | −$35.2M | −$43.1M | −$86.2M | −$116M |
| Capital expenditure | $0.0M | $0.2M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$18.0M | −$35.3M | −$43.1M | −$86.2M | −$116M |
| Share count change | 4,685.9% | 102.4% | 19.7% | 23.5% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $194M | $178M | $244M | $172M | $117M |
| Debt incl. finance leases | — | $0.0M | $30.7M | $29.4M | $31.2M |
| Shareholders' equity | $225M | $189M | $267M | $182M | $70.4M |
| Current ratio | 38.6x | 23.1x | 19.0x | 6.5x | 4.1x |
| Interest coverage | — | — | −105.2x | −28.0x | −29.3x |
| Returns and quality | |||||
| Return on capital | — | −319.9% | −90.5% | −227.0% | — |
| Return on equity | −97.4% | −20.7% | −23.0% | −45.6% | −96.2% |
| Return on tangible equity | −44.7% | −22.7% | −19.6% | −56.3% | −172.3% |
| Piotroski F-score | — | — | 2 | 1 | 1 |
| Altman Z'' | 49.1 | 26.8 | 7.8 | −0.2 | −12.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.6M
9 insiders
Of sales under plans
86%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Acumen Pharmaceuticals, Inc. · ABOS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.27 a share, the company is worth $164M.
Source: SEC EDGAR XBRL filings (CIK 0001576885). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.